Publications by authors named "Yaodi Hu"
Article Synopsis
- CAR-T cell therapy shows promise for treating blood cancers but struggles with solid tumors due to challenging tumor environments.
- This study identified that Nectin4 is overexpressed in many solid tumors and engineered new types of CAR-T cells (Nectin4-7.19 and FAP-12) that showed improved performance in targeting these cancers.
- The results indicated that Nectin4-7.19 CAR-T cells can effectively eliminate metastatic tumors in mouse models, especially when combined with FAP-12 CAR-T cells, suggesting these targets may enhance CAR-T therapy for solid tumors.
Adoptive immunotherapy based on chimeric antigen receptor-modified T cells (CAR-T) is one of the most promising strategies to treat malignant tumors, but its application in solid tumors is still limited. Glypican-3 (GPC3) is a meaningful diagnostic, therapeutic, and prognostic biomarker for hepatocellular carcinoma (HCC). The second/third generation GPC3-targeted CAR-T cells are generated to treat HCC.
View Article and Find Full Text PDF